Xencor, Inc. Hits New 52-Week High of $20.21, Marking Major Milestone

Xencor, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 20.21 on July 20, 2026. This achievement marks a notable increase from its 52-week low of USD 6.92, showcasing a substantial upward movement in the stock's performance over the past year. Despite this recent high, Xencor's one-year performance stands at -14.07%, contrasting sharply with the S&P 500's gain of 18.21% during the same period. The company's market capitalization is currently valued at USD 838 million, reflecting its position within the small-cap category. Financial metrics reveal that Xencor is currently loss-making, with a return on equity of -27.55% and a debt-to-equity ratio of -0.67. The stock does not offer a dividend yield, and its price-to-book ratio stands at 1.32. As Xencor continues to navigate the competitive landscape of the biotechnology industry, this recent high may serve as a pivotal point in its ongoing performance trajectory.